Global Oral Solid Dosage Pharmaceutical Formulation Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Oral Solid Dosage Pharmaceutical Formulation market size will reach US$ million by 2031.
Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Oral Solid Dosage Pharmaceutical Formulation Industry Forecast” looks at past sales and reviews total world Oral Solid Dosage Pharmaceutical Formulation sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Solid Dosage Pharmaceutical Formulation sales for 2025 through 2031. With Oral Solid Dosage Pharmaceutical Formulation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Solid Dosage Pharmaceutical Formulation industry.
This Insight Report provides a comprehensive analysis of the global Oral Solid Dosage Pharmaceutical Formulation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Solid Dosage Pharmaceutical Formulation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Solid Dosage Pharmaceutical Formulation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Solid Dosage Pharmaceutical Formulation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Solid Dosage Pharmaceutical Formulation.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Solid Dosage Pharmaceutical Formulation market by product type, application, key players and key regions and countries.
Segmentation by Type:
Immediate Release
Extended Release
Others
Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Gilead
Merck
Novartis
Pfizer
AbbVie
Boehringer Ingelheim
Please note: The report will take approximately 2 business days to prepare and deliver.
Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Oral Solid Dosage Pharmaceutical Formulation Industry Forecast” looks at past sales and reviews total world Oral Solid Dosage Pharmaceutical Formulation sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Solid Dosage Pharmaceutical Formulation sales for 2025 through 2031. With Oral Solid Dosage Pharmaceutical Formulation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Solid Dosage Pharmaceutical Formulation industry.
This Insight Report provides a comprehensive analysis of the global Oral Solid Dosage Pharmaceutical Formulation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Solid Dosage Pharmaceutical Formulation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Solid Dosage Pharmaceutical Formulation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Solid Dosage Pharmaceutical Formulation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Solid Dosage Pharmaceutical Formulation.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Solid Dosage Pharmaceutical Formulation market by product type, application, key players and key regions and countries.
Segmentation by Type:
Immediate Release
Extended Release
Others
Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Gilead
Merck
Novartis
Pfizer
AbbVie
Boehringer Ingelheim
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
95 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Oral Solid Dosage Pharmaceutical Formulation Market Size by Player
- 4 Oral Solid Dosage Pharmaceutical Formulation by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Oral Solid Dosage Pharmaceutical Formulation Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
